会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 52. 发明申请
    • ULTRASOUND CONTRAST AGENT DOSAGE FORMULATION
    • 超声对比剂剂量配方
    • US20070269381A1
    • 2007-11-22
    • US11834111
    • 2007-08-06
    • Richard WalovitchHoward BernsteinDonald ChickeringJulie Straub
    • Richard WalovitchHoward BernsteinDonald ChickeringJulie Straub
    • A61K49/22
    • A61K49/223
    • Clinical studies have been conducted and specific dosage formulations developed using polymeric microparticles having incorporated therein perfluorocarbon gases that provide significantly enhanced images of long duration. The dosage formulation includes microparticles formed of a biocompatible polymer, preferably including a lipid incorporated therein, and containing a perfluorocarbon that is a gas at body temperature. The microparticles are provided to a patient in an amount effective to enhance ultrasound imaging in the ventricular chambers for more than 5 minutes or in the mycocardium for more than a minute, in a dose ranging from 0.025 to 8.0 mg microparticles/kg body weight. Preferably the dose ranges from 0.05 to 4.0 mg microparticles/kg body weight. The dosage formulation typically is provided in a vial. A typical formulation is in the form of a dry powder that is reconstituted with sterile water prior to use by adding the water to the vial or syringe of the dry powder and shaking to yield an isosmotic or isotonic suspension of microparticles.
    • 已经进行了临床研究,并且使用其中结合有全氟化碳气体的聚合物微粒开发特定的剂型,其提供了长时间显着增强的图像。 剂量制剂包括由生物相容性聚合物形成的微粒,其优选包括掺入其中的脂质,并且含有在体温下作为气体的全氟化碳。 将微粒以有效量的方式提供给患者,剂量范围为0.025至8.0mg微粒/ kg体重的剂量,以在室室内超过5分钟或在心肌中增强超声成像超过一分钟。 剂量优选为0.05至4.0mg微粒/ kg体重。 剂型通常提供在小瓶中。 典型的制剂是干粉的形式,其在使用前通过将水添加到干粉末的小瓶或注射器中并且摇动以产生微粒的等渗或等渗悬浮液而在使用前用无菌水重构。
    • 53. 发明申请
    • Matrices Formed of Polymer and Hydrophobic Compounds For Use in Drug Delivery
    • 用于药物输送的聚合物和疏水性化合物形成的基质
    • US20070104656A1
    • 2007-05-10
    • US11617935
    • 2006-12-29
    • Howard BernsteinDonald ChickeringSarwat KhattakJulie Straub
    • Howard BernsteinDonald ChickeringSarwat KhattakJulie Straub
    • A61K9/14
    • A61K9/1617A61K9/1647Y10S514/951Y10S514/952
    • A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as compared to release from the polymeric matrix not incorporating the hydrophobic compound into the polymeric material. In contrast to methods in which a surfactant or lipid is added as an excipient, the hydrophobic compound is actually integrated into the polymeric matrix, thereby modifying the diffusion of water into the microparticle and diffusion of solubilized drug out of the matrix. The integrated hydrophobic compound also prolongs degradation of hydrolytically unstable polymers forming the matrix, further delaying release of encapsulated drug.
    • 将脂质或其它疏水性或两亲性化合物(本文统称为“疏水化合物”)整合到用于药物递送的聚合物基质中以改变药物释放动力学。 在药物是水溶性的实施方案中,与不将疏水化合物掺入聚合物材料的聚合物基质的释放相比,药物在更长的时间内释放。 与其中加入表面活性剂或脂质作为赋形剂的方法相反,疏水化合物实际上整合到聚合物基质中,从而改变水进入微粒的扩散并将溶解的药物扩散出基质。 整合的疏水化合物还延长了形成基质的水解不稳定聚合物的降解,进一步延缓了包封药物的释放。
    • 56. 发明授权
    • Controlled release of metal cation-stabilized interferon
    • 金属阳离子稳定的干扰素的控制释放
    • US06780434B2
    • 2004-08-24
    • US10092365
    • 2002-03-06
    • Mark A. TracyHoward BernsteinM. Amin Khan
    • Mark A. TracyHoward BernsteinM. Amin Khan
    • A61K910
    • B82Y5/00A61K9/1611A61K9/1647A61K38/212C07K14/56
    • This invention relates to a composition, and method of forming said composition, for the controlled release of interferon. The controlled release composition of this invention comprises a biocompatible polymer and particles of metal cation-stabilized interferon, wherein the particles are dispersed within the biocompatible polymer. The method of the invention, for producing a composition for the controlled release of interferon, includes dissolving a polymer in a polymer solvent to form a polymer solution, dispersing particles of metal cation stabilized-interferon particles in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of the interferon particles.
    • 本发明涉及用于控制释放干扰素的组合物和形成所述组合物的方法。 本发明的控释组合物包含生物相容性聚合物和金属阳离子稳定化干扰素颗粒,其中颗粒分散在生物相容性聚合物内。 本发明的制备用于干扰素控制释放的组合物的方法包括将聚合物溶解在聚合物溶剂中以形成聚合物溶液,将金属阳离子稳定的干扰素颗粒的颗粒分散在聚合物溶液中,然后固化聚合物 以形成含有干扰素颗粒的分散体的聚合物基质。
    • 58. 发明授权
    • Controlled release of metal cation-stabilized interferon
    • 金属阳离子稳定的干扰素的控制释放
    • US06379701B1
    • 2002-04-30
    • US09664299
    • 2000-09-18
    • Mark A. TracyHoward BernsteinM. Amin Khan
    • Mark A. TracyHoward BernsteinM. Amin Khan
    • A61K910
    • B82Y5/00A61K9/1611A61K9/1647A61K38/212C07K14/56
    • This invention relates to a composition, and method of forming said composition, for the controlled release of interferon. The controlled release composition of this invention comprises a biocompatible polymer and particles of metal cation-stabilized interferon, wherein the particles are dispersed within the biocompatible polymer. The method of the invention, for producing a composition for the controlled release of interferon, includes dissolving a polymer in a polymer solvent to form a polymer solution, dispersing particles of metal cation stabilized-interferon particles in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of the interferon particles.
    • 本发明涉及用于控制释放干扰素的组合物和形成所述组合物的方法。 本发明的控释组合物包含生物相容性聚合物和金属阳离子稳定化干扰素颗粒,其中颗粒分散在生物相容性聚合物内。本发明的用于制备用于控制释放干扰素的组合物的方法包括将 聚合物在聚合物溶剂中以形成聚合物溶液,将金属阳离子稳定的干扰素颗粒的颗粒分散在聚合物溶液中,然后固化聚合物以形成含有干扰素颗粒分散体的聚合物基质。